Clinical Trial Search

Primary: Change From Baseline to Week 13 (Day 85) in Inflammatory Rasch-built Overall Disability Scale (iRODS) Score — 0.234; 0.181 score on a scale (logits)

Primary: Time to First Confirmed Worsening on the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale — 721.0; 540.0 Days — p=0.9838

Primary: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 10; 10 Participants

Primary: Number of Participants With Any Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), Regardless of Causality — 76; 20 Participants

Primary: Epoch 1: Relapse Rate — 31.4; 9.7 percentage of participants — p==0.0045

Primary: Number of Participants With Survival — 66; 64 Participants

Primary: Muscle Strength

Primary: Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score — .7971 proportion of subjects

Primary: Change in C-reactive Protein — -0.04; -0.56 mg/L

Primary: ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS…

Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615

Primary: Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005) — 310; 182; 97 days — p=<0.001

Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…

Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008

Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale